ERBB2 and sarcoma: Two of the open trials target HER2 expressing sarcomas (NCT00902044, NCT00889954), while two more target GD2 expression (NCT01953900, NCT02107963); it remains to be seen whether similar successes seen in hematologic malignancies can be achieved in solid tumors.